Metsera, Inc. (MTSR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New York City, NY, United States. The current CEO is Christopher Whitten Bernard.
MTSR has IPO date of 2025-01-31, 93 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $7.43B.
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral hormone analog peptides designed to treat obesity, overweight, and related metabolic disorders. The company's pipeline includes MET-097i and MET-233i for obesity and overweight management, as well as MET-002, MET-224o, MET-067i, and MET-034i for treating conditions including diabetes and obesity. Founded in 2022 and based in New York, Metsera is advancing nutrient-stimulated therapeutic candidates toward clinical development.
